Patients with normal salt levels respond significantly better to glepaglutide treatment for short bowel syndrome, while those with low salt levels show little improvement from the medication. A 2026 analysis of 106 patients in the EASE SBS-1 trial found that glepaglutide reduced nutritional support needs in patients without salt depletion (p = 0.02) but not in salt-depleted patients. According to Gram Research analysis, correcting salt levels before starting glepaglutide may be necessary to achieve treatment benefits.
Researchers studied how a new medication called glepaglutide helps patients with short bowel syndrome, a serious digestive condition. They discovered something surprising: the medication worked much better for patients who had normal salt levels in their body compared to those with low salt levels. In a trial of 106 patients, those without salt depletion saw their need for nutritional support drop significantly when taking glepaglutide, while patients with low salt levels didn’t benefit as much. According to Gram Research analysis, this finding suggests doctors should check and correct patients’ salt levels before starting this treatment to get the best results.
Key Statistics
A 2026 analysis of 106 patients with short bowel syndrome found that 42% of patients without a colon were salt-depleted at baseline, compared to only 9% of patients who retained their colon.
In the EASE SBS-1 trial of 106 patients, glepaglutide significantly reduced the need for parenteral support in patients with normal salt levels (p = 0.02), but showed no significant benefit in salt-depleted patients.
Among 106 patients with short bowel syndrome in a 2026 clinical trial, salt depletion persisted in 89% of depleted patients (24 of 27) from baseline to week 24, with an odds ratio of 13.5.
The overall prevalence of salt depletion in short bowel syndrome patients increased from 25% at baseline to 36% by week 24 in a 106-patient trial of glepaglutide treatment.
The Quick Take
- What they studied: Whether a patient’s salt (sodium) levels affect how well a new medication called glepaglutide works for people with short bowel syndrome who need ongoing nutritional support.
- Who participated: 106 patients with short bowel syndrome and chronic intestinal failure who participated in a clinical trial. About 25% of them had low salt levels at the start of the study.
- Key finding: Patients with normal salt levels experienced significantly better results from glepaglutide, with greater reductions in their need for parenteral support (nutritional feeding through an IV). Patients with low salt levels showed little to no improvement from the medication.
- What it means for you: If you or someone you know has short bowel syndrome and might receive glepaglutide treatment, having normal salt levels before starting the medication appears important for it to work effectively. Talk to your doctor about checking salt levels before beginning treatment.
The Research Details
This study looked back at data from a large clinical trial called EASE SBS-1, which tested glepaglutide in 106 patients with short bowel syndrome. The original trial randomly assigned patients to receive either glepaglutide (given as injections once or twice per week) or a placebo (fake treatment) for 24 weeks. Researchers then divided patients into two groups based on their salt levels at the beginning of the study: those with normal salt and those with low salt levels. They compared how well the medication worked in each group by measuring changes in how much nutritional support patients needed.
The researchers measured salt levels using urine samples, which is a standard way to check if someone’s body has enough salt. They considered patients salt-depleted if their urine sodium was below 20 millimoles per liter or if their sodium-to-potassium ratio was less than 1. This approach allowed them to identify which patients might struggle with the medication before treatment even started.
The study adjusted for other factors that might affect results, including whether patients still had part of their colon (the large intestine), which can affect how the body absorbs nutrients and salt. By doing this, researchers could isolate the specific effect of salt levels on how well glepaglutide worked.
Understanding what factors make a treatment work better helps doctors use medications more effectively. If salt depletion reduces how well glepaglutide works, doctors can screen patients beforehand and correct salt levels before starting treatment, potentially helping more patients benefit from this medication.
This was a post-hoc analysis, meaning researchers looked at the data after the original trial was completed to answer a new question. While this approach can reveal important patterns, it’s not as strong as a study designed specifically to test this question from the start. The sample size of 106 patients is moderate, which is reasonable for this type of analysis. The findings about salt depletion remaining stable over time (with an odds ratio of 13.5) are quite strong statistically.
What the Results Show
Patients without salt depletion who received glepaglutide showed significantly greater reductions in their need for parenteral support (nutritional feeding through an IV) compared to those receiving placebo. The difference was statistically significant with a p-value of 0.02, meaning this result was unlikely to happen by chance. In contrast, patients who started the study with low salt levels showed no significant improvement from glepaglutide compared to placebo, suggesting the medication simply didn’t work as well for them.
The study also found that salt depletion was more common in certain patients: 42% of patients without part of their colon were salt-depleted at the start, compared to only 9% of patients who still had their colon. This makes biological sense because the colon plays an important role in absorbing salt and water from food.
Another striking finding was that salt depletion tended to persist. Patients who started the study with low salt levels were very likely to still have low salt levels at week 24, even after receiving glepaglutide. The odds ratio of 13.5 indicates this pattern was very strong and unlikely to be due to chance.
While patients without salt depletion who received glepaglutide were numerically more likely to achieve a clinical response (defined as at least a 20% reduction in nutritional support needs), this difference didn’t quite reach statistical significance (p = 0.12). This suggests a trend toward better outcomes but requires confirmation in future studies. The overall prevalence of salt depletion in the entire study group increased from 25% at baseline to 36% by week 24, indicating that salt depletion may worsen over time in these patients.
This finding adds an important new dimension to understanding glepaglutide’s effectiveness. Previous research showed that glepaglutide helps patients with short bowel syndrome by increasing nutrient absorption and reducing dependence on parenteral support. This study suggests that a patient’s baseline salt status is a critical factor determining whether they’ll benefit from the medication. This type of patient-specific factor is increasingly recognized as important in precision medicine, where treatments are tailored based on individual characteristics.
This was a post-hoc analysis, meaning the original trial wasn’t specifically designed to test the salt depletion question. The sample size of 106 patients, while reasonable, limits how confident we can be about the findings. The study was retrospective, looking back at existing data rather than prospectively following patients. Additionally, the study only looked at one type of short bowel syndrome patient (those with chronic intestinal failure), so results may not apply to all patients with this condition. The mechanism explaining why salt depletion reduces glepaglutide’s effectiveness wasn’t explored in this analysis.
The Bottom Line
Based on this research, doctors should consider checking patients’ salt levels before starting glepaglutide treatment for short bowel syndrome. If salt levels are low, correcting them first may improve the medication’s effectiveness. This recommendation has moderate confidence because it comes from a post-hoc analysis rather than a trial specifically designed to test this intervention. Patients should discuss salt status and potential supplementation with their healthcare team before beginning glepaglutide.
This research is most relevant to patients with short bowel syndrome and chronic intestinal failure who are considering glepaglutide treatment, as well as their doctors. It’s particularly important for patients without a colon, who appear more likely to have salt depletion. The findings may also interest gastroenterologists, nutritionists, and other specialists who care for patients with severe digestive disorders.
The study measured changes over 24 weeks. Patients without salt depletion showed measurable improvements in their need for nutritional support within this timeframe. However, salt depletion itself appeared to be a persistent condition, with depleted patients likely remaining depleted at 24 weeks. Correcting salt levels before starting treatment would likely need to happen over weeks to a few months, though the exact timeline isn’t specified in this study.
Frequently Asked Questions
Does glepaglutide work for all short bowel syndrome patients?
Glepaglutide appears more effective for patients with normal salt levels. A 2026 trial of 106 patients found it significantly reduced nutritional support needs in non-depleted patients but showed minimal benefit for those with low salt levels.
What is salt depletion and why does it matter for this treatment?
Salt depletion means your body doesn’t have enough sodium. In short bowel syndrome patients, low salt levels appear to prevent glepaglutide from working effectively. Checking and correcting salt levels before treatment may improve outcomes.
How common is salt depletion in short bowel syndrome?
About 25% of short bowel syndrome patients had salt depletion at the start of a 2026 trial, but this increased to 36% by week 24. Patients without a colon were much more likely to be salt-depleted (42% vs. 9%).
Can salt depletion be corrected before starting glepaglutide?
The study didn’t test whether correcting salt levels improves glepaglutide’s effectiveness, but the findings suggest it may help. Discuss salt supplementation strategies with your doctor before beginning treatment.
How long does glepaglutide take to work if salt levels are normal?
The 2026 trial measured changes over 24 weeks. Patients with normal salt levels showed measurable improvements in their need for nutritional support within this timeframe, though individual results vary.
Want to Apply This Research?
- Track weekly urine sodium levels or serum sodium measurements if your healthcare provider recommends monitoring. Record the specific values and dates to share with your doctor and identify trends over time.
- Work with your healthcare team to adjust dietary salt intake or take salt supplements as recommended before starting glepaglutide treatment. Log your salt intake and any symptoms related to salt depletion (such as weakness or dizziness) to monitor your progress.
- Set monthly reminders to review your sodium levels with your doctor. Track changes in your need for parenteral support and correlate these with your sodium status. Document any adjustments to salt supplementation and their effects on your overall nutrition and energy levels.
This article summarizes research findings and is not medical advice. Short bowel syndrome is a serious medical condition requiring specialized care. Before starting glepaglutide or making changes to salt intake or nutritional support, consult with your gastroenterologist or healthcare provider. Individual responses to treatment vary, and your doctor can assess whether this medication and these recommendations are appropriate for your specific situation. Do not adjust salt intake or stop nutritional support without medical supervision.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.